" class="no-js "lang="en-US"> 3Spine - Medtech Alert
Tuesday, September 16, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
3Spine | Pharmtech Focus

3Spine

About 3Spine

3Spine
3Spine is a privately-held medical device company offering MOTUS and the BalancedBack Total Joint Replacement procedure, an alternative to spinal fusion for patients suffering from leg and back pain.

Related Story

Clinical Trials

 3Spine

3Spine, Inc. Completes First US Surgeries

June 30 2022

3Spine, Inc., a medical device company developing total joint replacement for the lumbar spine, today […]